Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation

Starting soon · Not applicable

Conditions studied: Atrial Fibrillation (AF), Cardiac Amyloidosis

In brief

This study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac amyloidosis. The study targets on atrial fibrillation(AF) patients with "red-flag" indicators. Participants are randomized 1:1 into either an early screening or usual care group. * Early screening group : AI- ECG and/or CT-ECV analysis + AF treatment * Usual care group : AF treatment Both groups followed for 2 years to compare CA detection rates and clinical outcomes.

Key facts

Study ID

NCT07567508

Run by

Samsung Medical Center

People needed

500

Starts

2026-05-01

Expected to finish

2029-12-31

Last updated by the study team

2026-05-05

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 19 or older who have provided voluntary written informed consent.
• Patients with a history of AF (paroxysmal or persistent) and one or more red-flag symptoms/signs.
• Patients who can undergo at least one of the following: AI-ECG analysis or CT-ECV analysis.

You may not qualify if…

• Patients previously diagnosed with cardiac amyloidosis (AL or ATTR).
• Patients with severe heart failure (NYHA class IV) or terminal illness with a life expectancy of less than 1 year.
• Patients deemed inappropriate for participation by the investigator.

Where it is running

• Samsung Medical Center — Seoul, Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.